Sickle Cell & Stroke Risk: Gene Therapy Hope
- A new study suggests that gene therapy could offer a more substantial and lasting protective effect on brain health for individuals with sickle cell disease, potentially reducing stroke...
- The research compares favorably to existing treatments like hydroxyurea and blood transfusions.
- Bone marrow transplants also normalize brain blood flow in the long run.
Gene therapy shows meaningful promise for individuals battling sickle cell disease by perhaps reducing their stroke risk factors. A new study reveals that gene therapy offers a more durable impact on brain health, surpassing the effects of existing treatments such as hydroxyurea and blood transfusions. this growth could revolutionize treatment options.Researchers observed a lasting return to normal blood flow in patients enrolled in the study, similar to bone marrow transplants. The findings support the inclusion of stroke-risk patients in clinical trials for gene therapy. News Directory 3 reports this exciting news. Are you ready to learn more about sickle cell disease and stroke risk? Discover what’s next …
Gene Therapy Shows Promise for Improving Brain Blood Flow in Sickle Cell Disease
Updated June 28, 2025
A new study suggests that gene therapy could offer a more substantial and lasting protective effect on brain health for individuals with sickle cell disease, potentially reducing stroke risk factors. The findings offer a promising alternative for patients at risk.
The research compares favorably to existing treatments like hydroxyurea and blood transfusions. Hydroxyurea, a common treatment, has a limited impact on brain blood flow. While blood transfusions show a stronger positive effect, it’s temporary, requiring continuous transfusions. Researchers found that gene therapy has a more important and durable impact.
Bone marrow transplants also normalize brain blood flow in the long run. While the study didn’t directly compare gene therapy and bone marrow transplantation, results suggest both treatments lead to a similar, lasting return to normal blood flow.
The study, involving three patients, offers preliminary evidence of gene therapy’s effect on stroke risk. Further studies are needed to confirm these results. However, it adds to growing evidence that gene therapy should be considered a treatment option to protect brain health in patients with sickle cell disease.
The study supports new clinical trials for sickle cell disease gene therapy, including patients at risk for stroke, who have historically been excluded from such trials.
“We now have emerging data to at least evaluate the efficacy of gene therapy in patients with a risk of or history of stroke,” said Dr. Akshay Sharma,St. Jude Department of Bone Marrow Transplantation and Cellular Therapy. “Until now, we only had one option that had a long-term impact on blood flow in the brain: bone marrow transplantation. But now we may also have gene therapy as another viable method to protect against neurovascular disease in people with sickle cell disease.”
What’s next
Researchers are advocating for expanded clinical trials to further evaluate the efficacy of gene therapy in a broader patient population, particularly those with a history or high risk of stroke related to sickle cell disease.